What does this research mean for the field?

Janus kinase inhibitors significantly improve disease activity in active systemic lupus erythematosus but are associated with an increased risk of serious infections, particularly herpes zoster, with no evident increase in venous thromboembolism. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review aims to evaluate the efficacy and safety of Janus kinase inhibitors in patients with active systemic lupus erythematosus.

June 6, 2026JCR Journal of Clinical Rheumatology

Efficacy and Safety of Janus Kinase Inhibitors in Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized Controlled Trials

View Full Paper

Ask AI

Bookmark

This review aims to evaluate the efficacy and safety of Janus kinase inhibitors in patients with active systemic lupus erythematosus.
Conducted a systematic review of randomized, double-blind, placebo-controlled trials
Included five trials with a total of 1802 participants
Evaluated JAKi drugs including baricitinib, deucravacitinib, and upadacitinib
JAKi improved SRI-4 response compared to placebo (54.4% vs. 43.8%; OR: 1.78, 95% CI: 1.41-2.25; p<0.001)
BICLA response improved with JAKi (OR: 1.92, 95% CI: 1.53-2.41)
Increased rates of serious adverse events (OR: 1.48, 95% CI: 1.03-2.13) and serious infections (OR: 2.10, 95% CI: 1.21-3.65) observed with JAKi.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial assesses JAKi efficacy in systemic lupus erythematosus, indicating disease improvement with safety concerns.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a23bb4471a5da9775e76cbd https://doi.org/10.1097/rhu.0000000000002368

View Full Paper

Ask AI

Bookmark

Efficacy and Safety of Janus Kinase Inhibitors in Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Key Points

Discussion

Implication

Cite This Study

Efficacy and Safety of Janus Kinase Inhibitors in Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider